Genetic study of drug-resistant lung cancer
Part of Brain & nervous system, Cancer clinical trials.
This trial looks at the genetic changes in non-small cell lung cancer (NSCLC) that has stopped responding to targeted therapy pills. It aims to understand why the cancer became resistant, which may help find better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) with a specific gene mutation (like EGFR, ALK, KRAS, etc.).
- You have been treated with a targeted therapy pill (TKI) and your cancer has gotten worse while on it.
- You have a tumor sample (from a biopsy or surgery) that can be tested for genetic changes.
- You are willing to give a blood sample for genetic testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This study is for people with advanced non-small cell lung cancer whose tumors do not have certain genetic changes (called driver mutations) and whose first treatment did not work well or caused bad side effects within 6 months. The researchers want to use a special test (DNA/RNA-NGS) to look for hidden genetic alterations that might explain why the cancer didn't respond.
This trial looks at the “molecular landscape,” meaning the specific gene changes driving your lung cancer, for people whose non-small cell lung cancer (NSCLC) has rare mutations. The goal is to better understand what those rare changes mean and how they could guide treatment decisions.
Hear when a new EGFR Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.